Clinical Trials Logo

Leukemia, Prolymphocytic, T-Cell clinical trials

View clinical trials related to Leukemia, Prolymphocytic, T-Cell.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05010005 Active, not recruiting - Clinical trials for T-cell Large Granular Lymphocyte Leukemia

A Study of Ruxolitinib and Duvelisib in People With Lymphoma

Start date: August 12, 2021
Phase: Phase 1
Study type: Interventional

This study will test the safety of ruxolitinib, given at one dose that does not change, and duvelisib, given at different doses, to find out what effects, if any, the study treatment has on people with relapsed or refractory NK-cell or T-cell lymphoma.

NCT ID: NCT04526795 Active, not recruiting - Clinical trials for Refractory Acute Myeloid Leukemia

Fludarabine, Cytarabine, and Pegcrisantaspase for the Treament of Relapsed or Refractory Leukemia

Start date: April 9, 2021
Phase: Phase 1
Study type: Interventional

This phase Ib trial investigates the side effects and best dose of pegcrisantaspase when given together with fludarabine and cytarabine for the treatment of patients with leukemia that has come back (relapsed) or has not responded to treatment (refractory). Pegcrisantaspase may block the growth of cancer cells. Chemotherapy drugs, such as fludarabine and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pegcrisantaspase in combination with fludarabine and cytarabine may work better in treating patients with leukemia compared to the combination of fludarabine and cytarabine.

NCT ID: NCT03989466 Active, not recruiting - Clinical trials for T-Cell Prolymphocytic Leukemia

Itacitinib and Alemtuzumab in Treating Patients With T-Cell Prolymphocytic Leukemia

Start date: January 15, 2020
Phase: Phase 1
Study type: Interventional

This phase Ib trial studies the side effects and best dose of alemtuzumab when given together with itacitinib in treating patients with T-cell prolymphocytic leukemia. Itacitinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Immunotherapy with alemtuzumab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Giving itacitinib and alemtuzumab may work better in treating patients with T-cell prolymphocytic leukemia compared to standard of care treatment.